Powered by GPT and Fine-Tuned to Allurion’s
Proprietary Behavior Change Program
Allurion invites attendees of the IFSO
conference in Naples, Italy (August 30 to September 1, 2023) to
experience Coach Iris at booth #509-510
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to
ending obesity, has today unveiled Coach Iris, a new generative
AI-powered health coach designed to enhance outcomes within the
Allurion Program and maximize clinic efficiency. Built in close
collaboration with leading global weight-management professionals
and Allurion’s behavioral scientists, Coach Iris is intended to
instantly expand the care team by providing always-on support,
education, and motivation.
Allurion is committed to offering new digital tools and services
to enhance weight loss results and satisfaction. Delivered via the
Allurion App, the company believes that Coach Iris can serve as a
powerful complement to care providers, empowering patients with
24/7 access to personalized support and guidance. Upon launching
the Allurion App, patients are free to initiate a conversation with
Coach Iris on a broad range of health and weight-loss topics. For
example, patients can ask for tailored meal plans, recipes,
exercise routines, stress management techniques, and motivational
insights.
Allurion prioritizes accuracy and safety for a diverse set of
consumers. “By designing Coach Iris to solve the specific needs of
consumers seeking weight loss, we anticipate increasing the
accuracy of Coach Iris by reducing the risks of potentially
inaccurate edge cases, and also ensuring that appropriate safety
and review mechanisms are in place,” said Jeff Feldgoise,
Allurion’s Senior Vice President of Digital.
In addition to responding to patient requests, Coach Iris is
designed to proactively reach out to ensure patients remain
actively engaged in their weight loss program, leading to
longer-lasting commitment and more successful outcomes. Allurion
believes Coach Iris will become a trusted companion, available for
patients whenever they need assistance, motivation, or simply an
empathetic ear, so they never feel alone on their weight loss
journey.
“Our digital tools are underpinned by our unique and proprietary
dataset collected across 80 countries. We are fully committed to
giving our clinics the best AI weight-management tools to
strengthen their care delivery and propel the Allurion Program to
new levels of effectiveness,” said Dr. Shantanu Gaur, Founder and
Chief Executive Officer of Allurion. "Coach Iris is an example of
us bringing this vision to life, improving the consumer experience,
while simultaneously aiming to make our healthcare professionals
more productive and capable of delivering exceptional care to a
much larger number of patients.”
Allurion invites attendees of the International Federation for
the Surgery of Obesity and Metabolic Disorders (IFSO) conference in
Naples, Italy, to experience Coach Iris firsthand at booth
#509-510. They will be able to witness how this powerful AI-powered
health coach improves the patient care experience within the
Allurion Program, with the aim of driving unprecedented patient
success.
Coach Iris will be available at no additional charge by October
2023 for clinics that subscribe to the Allurion Virtual Care Suite
VCS+ or VCS Custom plans.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight-loss platform that combines the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less gastric
balloon for weight loss, the Allurion Virtual Care Suite, including
the Allurion Mobile App for consumers, Allurion Insights for
healthcare providers featuring the Iris AI Platform, and the
Allurion Connected Scale and Health Tracker devices. The Allurion
Virtual Care Suite is also available to providers separately from
the Allurion Program to help customize, monitor and manage
weight-loss therapy for patients regardless of their treatment
plan: gastric balloon, surgical, medical or nutritional. The
Allurion Gastric Balloon is an investigational device in the United
States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com. Allurion is a trademark of
Allurion Technologies, Inc. in the United States and countries
around the world.
Forward-Looking Statements
This press release may contain certain forward-looking
statements within the meaning of the federal securities laws. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions and include statements regarding Allurion’s
expectations for, and market acceptance of, the Allurion Program.
They reflect the current beliefs and assumptions of Allurion’s
management based on information currently available to them.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future results
or developments to differ materially from the forward-looking
statements in this communication, including but not limited to (i)
the ability of Allurion to obtain regulatory approval for and
successfully commercialize the Allurion Program, (ii) the results
of clinical data from its studies, (iii) the evolution of the
markets in which Allurion competes, (iv) the ability of Allurion to
defend its intellectual property and satisfy regulatory
requirements, (v) the impact of the COVID-19 pandemic on Allurion’s
business, (vi) Allurion’s expectations regarding its market
opportunities and (vii) the risk of downturns and a changing
regulatory landscape in the highly competitive industry in which
Allurion operates. The foregoing list of factors is not exhaustive.
You should carefully consider the foregoing factors and the other
risks and uncertainties described in the “Risk Factors” section of
the proxy statement/prospectus contained in Allurion’s Registration
Statement on Form S-4 (333-271862), the company’s Form 8-K filed on
August 7, 2023 (as amended), and other documents filed by Allurion
from time to time with the U.S. Securities and Exchange Commission.
These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Allurion assumes no obligation and does not intend
to update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Allurion
does not give any assurance that it will achieve its
expectations.
www.allurion.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230829317353/en/
Media Contacts
Global: Cedric Damour PR Manager +33 7 84 21 02 20
cdamour@allurion.com
US: Erik Milster SeriesM PR 508.740.6125
emilster@seriesmpr.com
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Dec 2023 to Dec 2024
